
|Articles|August 28, 2015
New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review
Author(s)Davy James, Managing Editor
Top stories of the week on Specialty Pharmacy Times.
Advertisement
[<a href="//storify.com/pharmacytimes/pcsk9-approval-biosimilar-cost" target="_blank">View the story "New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review" on Storify</a>]
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Notifies Flu Vaccine Makers to Add Warning for Increased Febrile Seizure Risk in Young Children Day Following Vaccination
2
Oral Semaglutide Approved to Reduce the Risk of Cardiovascular Events
3
AI-Powered Digital Twins Offer a New Window Into Tumor Metabolism in Brain Cancer
4
In 2026, Pharmacists Will Be Driving Change Across the Care Continuum
5














































































































































































































